Howe Jill Ann
SEC insider (Form 3/4/5 filer). CIK 0001892397. Chief Financial Officer at Lineage Cell Therapeutics, Inc. (LCTX). 3 reported Form 4/5 transactions since Sep 2024; latest on Mar 5, 2026. Located in CARLSBAD, CA.
Companies Howe Jill Ann has filed insider reports for
- Lineage Cell Therapeutics, Inc. (LCTX): Officer, Chief Financial Officer
Howe Jill Ann
CIK: 0001892397
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
Lineage Cell Therapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (3 total)
- Mar 5, 2026LCTX
Lineage Cell Therapeutics, Inc.
AwardDirectEmployee Stock Option (Right to Buy)
1.1M shares- - Mar 10, 2025LCTX
Lineage Cell Therapeutics, Inc.
AwardDirectEmployee Stock Option (Right to Buy)
750K shares- - Nov 26, 2024LCTX
Lineage Cell Therapeutics, Inc.
PurchaseDirect15K shares at avg. $0.59$9K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 5, 2026 | LCTX Lineage Cell Therapeutics, Inc. | Award Employee Stock Option (Right to Buy) | 1,050,000 | - | - | Direct |
| Mar 10, 2025 | LCTX Lineage Cell Therapeutics, Inc. | Award Employee Stock Option (Right to Buy) | 750,000 | - | - | Direct |
| Nov 26, 2024 | LCTX Lineage Cell Therapeutics, Inc. | Purchase | 15,000 | $0.59 | $8,850 | Direct |
1-3 of 3 transactions